66548-62-7

Upstream product

• 6000-59-5 glyoxalic acid monohydrate 
• 349-76-8 3'-(trifluoromethyl)acetophenone 
• 1423-26-3 (meta-(trifluoromethyl)phenyl)boronic acid 
• 66548-63-8 6-(α,α,α-trifluoro-m-tolyl)-3-chloropyridazine 

Downstream Products

• 1357589-34-4 2-(1-phenyl-1H-pyrazol-5-yl)-6-[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one 
• 66548-63-8 6-(α,α,α-trifluoro-m-tolyl)-3-chloropyridazine 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS

The present invention discloses a fused heterocyclic compound of formula (I) wherein, R1, G1, G2, G3, G4, A1, A2, Q, n and Z are as defined in the detailed description. The prese

Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors

We report a series of phenyl substituted pyridazin-3-ones substituted with morpholino-pyrimidines. The SAR of the phenyl was explored and their c-Met kinase and cell-based inhibitory activity toward c-Met driven cell lines were evaluated. Described herein

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. A compound represented by the formula (1x): wherein each symbol is as des

Method for treating anxiety in mammals

This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.

6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents

This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.

Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates

This disclosure describes novel alkyl 3-[6-(aryl)-3-pyridazinyl]-carbazates useful as hypotensive agents in mammals. SP CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation of our copending application Ser. No. 692,254, filed June 3, 1976 now abandoned, which in turn is a continuation-in-part of our abandoned application Ser. No. 552,024, filed Feb. 24, 1975 now abandoned.